MUC1*-ADC / Minerva Biotech - LARVOL DELTA

MUC1*-deruxtecan kills tumors that have acquired resistance to trastuzumab containing therapeutics (AACR 2025) - "Purpose: To develop a treatment for HER2 positive patients whose tumors have stopped responding to Enhertu HER2 positive BT474 breast cancer cells were induced to become Herceptin resistant (trastuzumab resistant) in vitro via prolonged exposure to sub-lethal levels of the drug. Patients with HER2 positive breast cancers have benefitted greatly from the new ADC Enhertu (fam-trastuzumab deruxtecan). However, most patients, develop resistance to HER2-directed therapies and experience progressive disease leaving them with few treatment options. Here we've shown that HER2 positive breast cancer cells acquire resistance to trastuzumab by increasing expression of the powerful growth factor receptor MUC1*."

IO biomarker • Preclinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • MUC1

MUC1*-ADCs are effective against heterogeneous solid tumor cancers (AACR 2024) - "Greatest efficacy was observed for breast cancer xenografts with an H Score >10 treated with MNC2-Deruxtecan... These data, combined with MNC2-CAR T data from our 1st-in-human trial for metastatic breast cancer, supports a conclusion that the MUC1* antibody MNC2 is safe and could have high therapeutic value as a MUC1*-ADC for multiple solid tumors with both high and low antigen density."

ADC • Heterogeneity • Breast Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • MUC1